|
KMID : 1216720130050010018
|
|
Korean Journal of Gynecologic Endocrinology
2013 Volume.5 No. 1 p.18 ~ p.26
|
|
|
The Relationship Between Leptin and Adrenergic Receptors Genes Polymorphisms and Changes in Production of Osteoprotegerin and Soluble Receptor Activator of NF-κB by Whole Blood Cells after Hormone Therapy
|
|
Park Kyung-Eui
Lee Hee-Jun
Kim Hoon
Ku Seung-Yup
Kim Seok-Hyun
Choi Young-Min
Kim Jung-Gu
|
|
|
Abstract
|
|
|
Objectives: To investigate the relationship between single nucleotide polymorphisms (SNPs) in leptin and adrenergic receptors genes, and the production of osteoprotegerin (OPG) and soluble receptor activator of NF-κB ligand (sRANKL) by whole blood cells (WBC) after hormone therapy (HT) in postmenopausal Korean women.
Methods: The leptin receptor c.326A>G, c.668A>G, c.1968G>C SNPs, β2 adrenergic receptor c.46A>G, c.79C>G SNPs, and β3 adrenergic receptor c.190T>C SNP were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and Taqman assay in postmenopausal Korean women. The production of OPG and sRANKL by lipopolysaccharide (LPS)-stimulated WBC before (n=149) and after (n=73) estrogen-progestogen therapy of 6 months were also measured.
Results: At baseline, the production of OPG and sRANKL by LPS-stimulated WBC, and in ratios of sRANKLx1,000/ OPG were not different according to leptin and β2 adrenergic receptors genetic polymorphisms, but the TT genotype of β3 adrenergic receptor c.190T>C SNP showed significantly lower OPG production than non-TT genotype. Among SNPs measured, the β2 adrenergic receptor c.46A>G SNP only was related with changes in the production of sRANKL by WBC after HT of 6 months. The production of sRANKL by WBC after HT decreased significantly in AA genotype of β2 adrenergic receptor c.46A>G SNP, compared to other genotypes.
Conclusion: The β3 adrenergic receptor c.190T>C SNP is related with the production of OPG by WBCs before HT, whereas the β2 adrenergic receptor c.46A>G SNP affects the changes in the production of sRANKL by WBCs after HT.
|
|
|
KEYWORD
|
|
|
Adrenergic receptor, Hormone therapy, Leptin, Osteoprotegerin, Polymorphism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|